Welcome to the CardiOCare project.
An interdisciplinary approach for the management of the elderly multimorbid patient with breast cancer therapy induced cardiac toxicity: Aged-related factors and co-morbidities increase elderly breast cancer patients’ vulnerability to cardiotoxicity due to cancer treatment. Lack of best practices and frailty bias in these patients, underrepresented in trials, may lead to inappropriate interventions and undertreatment, resulting in poorer outcomes, deterioration of QoL and increased healthcare costs. The EU-funded CARDIOCARE project will focus on the elderly breast cancer population and through a holistic approach including eHealth applications, wearable sensors and biomarkers will provide the ability to patients to take part in their care process and enhance their physical and mental health, contributing to an individualised care plan and a psychological adaptation to their disease. CARDIOCARE will enable effective risk stratification mitigating cardiotoxicity and adverse events, minimising hospitalisation and enhancing QoL
Welcome by the Coordinating Team
We are excited to lead an international effort aiming to improve the monitoring, treatment and overall care provided to breast cancer patients above 65 years of age who are at higher risk of cardiac toxicity from cancer therapy. We envisage that the use of advanced clinical, laboratory and computer methods by the scientists involved in the project, will greatly increase our understanding of the complex needs of breast cancer patients and their caregivers, and help build a risk assessment tool in order to improve our care strategies, minimize adverse events and enhance cancer patients’ quality of life.
The Coordinating Team
Dimitrios I. Fotiadis
Clinical Study Manager
Euros (Overall Budget)
Grant Agreement Nr.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme
Healthcare interventions for the management of the elderly multimorbid patient